Mayne Pharma is proud to share that we’re an exhibiting partner at the 2024 ACannabis Conference in Melbourne Australia from 12 to 13 March. Our friendly and knowledgeable team will be at Stand 17 to discuss your Medicinal Cannabis needs and showcase our development and manufacturing capabilities delivered from our FDA and TGA approved facility in Adelaide, South Australia. Register today at http://acannabis.com.au or reach out directly to our BD team at [email protected] We look forward to seeing you there.
Mayne Pharma Services
Pharmaceutical Manufacturing
Customer-focused, full-service, Australian based, CDMO specialising in oral and topical dosage forms.
Über uns
We are a customer-focused, full-service, global, contract development and manufacturing organisation (CDMO) specialising in pharmaceutical development of oral and topical dosage forms. Part of Mayne Pharma Group Limited, we have a 40-year proud history of successfully developing and manufacturing oral and topical products. We manufacture for the global market to rigorous pharma industry standards, using best practice techniques and specialised equipment. With over 30 existing customers, we partner with clients to help take their pharmaceutical products from concept to commercialisation quickly and cost-effectively. Our highly-skilled and dedicated team of scientists and project managers offers individualised contract development and manufacturing services for our clients. This includes pharmaceutical formulation, analytical development, clinical trial supplies, scale-up of new formulations, technology transfer of products and commercial production. We are FDA and TGA accredited and have mutual agreements with MHRA, Health Canada and other European and Asian authorities. We have a proven commercialisation track record - demonstrated by more than 70 product launches globally over the last decade. Our facility is located in South Australia, meaning you may be eligible to take advantage of current Australian Government tax incentives. Our proven experience in generating intellectual property can help accelerate your program’s patent protection goals. If you’re looking for a tailored solution for your pharmaceutical project, we’re here to support you take the next step.
- Website
-
http://maynepharmaservices.com
External link for Mayne Pharma Services
- Industrie
- Pharmaceutical Manufacturing
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Salisbury South
- Typ
- Öffentliches Unternehmen
- Gegründet
- 1983
Standorte
-
Salisbury South, 5106, AU
Employees at Mayne Pharma Services
Aktualisierungen
-
Mayne Pharma Services reposted this
New on Pharma's Almanac: Mayne Pharma Services' Grant Swart explains how Mayne delivers innovation and end-to-end solutions that accelerate drug development, exemplifying the benefits of partnering with Australian CDMOs and the nation's rising prominence in the pharmaceutical sector. #cdmo #pharma #osd #australia #clinicalsupply #speedtoclinic #spraydrying
-
CPhI 2023 in Barcelona The Mayne Pharma Services team will be present in Barcelona for CPhI 25 – 28 October. The team will be available to discuss their development and manufacturing capabilities including: oral solid dose including spray drying, liquids, creams, ointments and nasal sprays. With both blister and bottling capabilities, Mayne Pharma offers a fully integrated service. The team will also be on hand to discuss potential tax incentives and a favourable regulatory and business environment available in Australia. If you would like to meet with a member of our BD team, please contact us via: [email protected] We look forward to seeing you there. #CPHIBarcelona2023, #CDMO